APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Intimation Regarding Payment Of Interest In Terms Of Regulation 57(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
As per annexure enclosed08-03-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sir, Sub: Intimation in terms of Regulation 39(3) of the SEBI (LODR) Regulations, 2015 (Regulations) regarding loss of share certificate. This is to inform you that the Company has received intimation from shareholder on March 4, 2022 regarding loss of share certificate. In accordance with Regulation 39(3) of the Regulations, the details of the said share certificates are as given below: Folio No. Name of the Shareholder(s) No of equity shares held Share Certificate No. Distinctive Nos. 434 Anitha Medabalmi 50 350434 3632145 to 3632194 This is for your information.04-03-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suneeta Reddy03-03-2022
Apollo Hospitals to enter Nifty50 index on March 31; stock surges 7%
Apollo Hospitals Enterprises will replace state-owned oil marketing company Indian Oil Corporation in the index25-02-2022
Buy Apollo Hospitals Enterprise; target of Rs 5416: Geojit
Geojit is bullish on Apollo Hospitals Enterprise has recommended buy rating on the stock with a target price of Rs 5416 in its research report dated February 16, 2022.23-02-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sir, Sub: Intimation in terms of Regulation 39(3) of the SEBI (LODR) Regulations, 2015 (Regulations) regarding loss of share certificate. This is to inform you that the Company has received intimation from shareholder on February 22, 2022 regarding loss of share certificate. In accordance with Regulation 39(3) of the Regulations, the details of the said share certificates are as given below: Folio No. Name of the Shareholder(s) No of equity shares held Share Certificate No. Distinctive Nos. 5859 Panduranga D 200 355861 6374431 to 6374630 This is for your information.22-02-2022
Apollo Hospitals inks pact for tertiary care hospital in Uzbekistan
The partnership with Apollo Hospitals will provide quality healthcare for over 60 million people of Uzbekistan and bordering regions of Kyrgyzstan, Kazakhstan and Tajikistan, the private healthcare services provider, which is expanding its presence to the Central Asian country, said.18-02-2022
Buy Apollo Hospitals; target of Rs 5480: ICICI Direct
ICICI Direct is bullish on Apollo Hospitals has recommended buy rating on the stock with a target price of Rs 5480 in its research report dated February 14, 2021.15-02-2022
Q3FY22 Quarterly Result Announced for Apollo Hospitals Enterprise Ltd.
Apollo Hospitals Enterprise declares Q3FY22 result: Q3 FY22 Consolidated Revenues of Rs 36,389 mio (growth of 32% yoy). Q3 FY22 Consolidated EBITDA (Post Ind AS 116) of Rs 5,870 mio. New Hospitals (excl Proton) reported an EBITDA of Rs 1,189 mio in Q3 FY22 as compared to an EBITDA of Rs 645 mio in Q3 FY21. Proton reported EBITDA (Post Ind AS 116) of Rs 156 mio in Q3 FY22 as compared to EBITDA of Rs 17 mio in Q3 FY21. AHLL reported EBITDA (Post Ind AS 116) of Rs 495 mio in Q3 FY22 as compared to EBITDA Rs 278 mio in Q3FY21. Consolidated PAT of Rs 2,284 mio in Q3 FY22. Ind-AS 116 on operating lease impacted reported PBT in Q3FY22 to the extent of Rs 107 mio Q3FY22 occupancy across the group was at 5,107 beds (65% occupancy) as compared to 4,658 beds (63% occupancy) in Q3FY21. The Q3FY22 occupancy in mature hospitals was at 3,575 beds (66% occupancy). New hospitals had an occupancy of 1,532 beds (63%) occupancy) in Q3FY22. Inpatient Volumes across the group increased by 28% from 99,197 to 127,441. ARPOB (excluding vaccination) was at Rs 46,062 Vs Rs 40,092 registering a growth of 15% in Q3 FY22 as compared to the same period previous year. Q3FY22 Consolidated Revenues at Rs 36,389 mio Q3FY22 Consolidated EBITDA at Rs 5,870 mio Q3FY22 Consolidated PAT at Rs 2,284 mio Result PDF14-02-2022